KTD-092
KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases[1].
Product Specifications
UNSPSC
12352005
Target
DYRK
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Neurological Disease
Smiles
CCN1C=NN=C1C2=NC(NC(C3=CC(OC)=C(C=C3OC)OC)=O)=CC=C2
Molecular Formula
C19H21N5O4
Molecular Weight
383.40
References & Citations
[1]Sujeong Hong, et al. Discovery of 2- (1,2,4-triazol-3-yl) pyridine KTD-092 as a novel DYRK1A. Wiley Online Library inhibitor. 2025.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DYRK1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15274815 1 Vial
Lentiviral mouse Paox shRNA (UAS) - Lentiviral mouse Paox shRNA (UAS, iRFP) (100)
Ask
View Details 
MBS1198657-01 0.02 mg (E-Coli)
Recombinant Haemophilus influenzae LexA repressor (lexA)
Ask
View Details MBS1198657-02 0.1 mg (E-Coli)
Recombinant Haemophilus influenzae LexA repressor (lexA)
Ask
View Details